The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (GlaxoSmithKline/Tesaro), result in a significant financial burden for payers. These costs are likely to increase with the expected label expansions of current therapies to new patient populations and the anticipated approval of AstraZeneca’s Imfinzi for newly diagnosed advanced ovarian cancer. As the number of high-priced therapies increases, understanding the market access drivers that are important to payers and oncologists will be essential to maximizing these therapies’ uptake.


  • How are Avastin and the PARP inhibitors positioned in the treatment algorithm? How have PARP inhibitors been adopted into physician prescribing patterns?
  • What is the formulary coverage of key brands for ovarian cancer, and what types of cost control have MCOs enacted?
  • What role does value assessment play in MCOs’ review of ovarian cancer drugs? Which types of information do MCOs use in their assessment?
  • What are physicians’ views on the key emerging therapies for ovarian cancer? What factors will most influence MCO coverage of an early-line PARP inhibitor-based therapy?


United States


  • Survey of 100 U.S. medical oncologists.
  • Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).


Avastin, Lynparza, Rubraca, Zejula, Imfinzi


  • Reimbursement and contracting.
  • Access and prescribing.
  • Special topics.
  • Opportunities and challenges for emerging therapies.


U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

Table of contents

  • Ovarian Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)
    • Access & Reimbursement Ovarian Cancer US April 2019

Author(s): Carolina do Pazo, M.Sc; Chris Lewis

Carolina do Pazo, M.Sc., is a Business Insights Analyst in the oncology division at Decision Resources Group. Prior to joining DRG, she completed a MSc in Biotechnology, Bioprocessing and Business Management with distinction at the University of Warwick, as a Chevening scholar. She also earned her first-class BSc and BEng in Biotechnology from the Universidad ORT. Ms. do Pazo has worked as a Research Scientist at the Institut Pasteur de Montevideo, analysing the ageing process of yeast cells, and has been part of a project between Indiana University and Universidad ORT that analysed the production of nanohybrids for drug delivery systems applications.

Chris Lewis serves as primary research manager, U.S. Access and Reimbursement, with responsibility for coordination, content review and content generation of the market access and reimbursement insights at DRG. Content is based on online surveys of managed care organizations and physicians and expert analysis of reimbursement and prescribing patterns of key therapies treating various disease states.

Lewis was an analyst/senior analyst for the group’s HealthLeaders-InterStudy subsidiary for eight years, specializing in the managed care and pharmacy benefit management industries. Throughout her tenure, she has produced the Health Plan Analysis reports for California, New York, New Jersey, Connecticut, and Pennsylvania and authored DRG’s series of pharmacy benefit manager profiles. She has also conducted numerous webinars for the group. She is a seasoned journalist with a B.A. in communications from California State University, Sacramento.

Related Reports

Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PA...

View Details

Ovarian Cancer | Disease Landscape and Forecast | G7 | 2020

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inh...

View Details

Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)

The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncolo...

View Details

Ovarian Cancer - Epidemiology - Mature Markets

DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We...

View Details